NewsNew booster study on Johnson & Johnson: protection against...

New booster study on Johnson & Johnson: protection against omicron amazing

In Germany it is only boosted with Biontech and Moderna. According to a booster study from South Africa, Johnson & Johnson also offers a high level of protection against omicrons.

The Standing Vaccination Committee (Stiko) now not only recommends a booster vaccination three months after the basic immunization* for everyone over the age of 18, but recently also for children and adolescents aged 12 to 17 years. The reason for this is that the corona vaccines lose significantly in effectiveness over time, as echo24.d e* reports.

So far, only the mRNA vaccines from Biontech and Moderna* have been used for boosting in Germany. In contrast to the vector vaccines AstraZeneca and Johnson & Johnson, the two mRNA vaccines are significantly more effective – at least for primary immunization. But when it comes to booster vaccination, the two vector vaccines don’t do as badly as initially thought. A new booster study from South Africa shows: A booster vaccination with Johnson & Johnson offers a high level of protection against omicrons.

Booster study from South Africa shows: Johnson & Johnson protects against omicron

Study results from South Africa have shown that a booster vaccination with Johnson & Johnson protects against a severe course of the disease in the case of a corona infection with the omicron variant B.1.1.529*, as reported by the editorial network Germany (RND) . Reuters first wrote about the booster study from South Africa.

In a study, the South African Medical Research Council (SAMRC) observed the course of the corona disease in a total of 477,234 healthcare workers. It was examined to what extent the number of hospital stays is reduced by a booster with Johnson & Johnson. All study participants have been shown to have been infected with the omicron variant during the fourth wave.

In addition, all participants received the corona vaccine from Johnson & Johnson as their first vaccination. About half of the study participants had also received a booster vaccination with Johnson & Johnson. The proportion of hospital stays in the boosted group and the non-boosted group were compared.

Booster with Johnson & Johnson provides 85 percent protection against severe omicron progressions

According to the study results, the booster vaccination with Johnson & Johnson reduced hospitalizations by 63 percent in the first two weeks after the booster. In a period of up to two months, the vaccination protection against a severe course of the disease increased significantly. Protection from hospitalization for Omicron infection rose to as much as 85 percent.

However, it remains unclear whether Johnson & Johnson is also suitable as a booster if the basic immunization was carried out with another vaccine. In general, it has already been shown that a booster cross-vaccination offers better omicron protection – a combo comes off particularly well.

According to study results, the vector vaccine from AstraZeneca offers a high level of protection against omicrons and performs well as a booster, as reports. According to another corona study, however, a vaccine is almost ineffective as a booster * and therefore completely unsuitable as a booster vaccine. * is an offer from IPPEN.MEDIA.

List of rubrics: © Daniel Karmann/dpa/Symbolbild

To swim with sharks! This is how entrepreneurs float in the face of inflation

The most successful entrepreneur, and the one who can swim and fall in love with sharks, is the one who is willing to learn from every moment of his process, points out Luis Arandia.

#Between the lines | COVID-19. The sixth wave is coming and a (new) variant...

It is not possible to declare when the sixth wave will arrive in Mexico, but now, more than ever, it is urgent that virological surveillance be maintained, points out Jonathán Torres.

In the new reality, brands must establish messages of closeness

The diffusion of modifications to the organizational culture in the face of a new scenario will be successful if it is underpinned by transparent, close and reliable communication, considers Mario Maraboto.

Covid-19: The end of the pandemic is in sight, says the WHO

Tedros Adhanom Ghebreyesus highlighted that last week the number of weekly deaths fell to its lowest level since March 2020.

#Between the lines | The (yet) unsolved mystery of COVID-19

Suddenly it seems that there is a battle between specialists from different medical specialties to see who announces the next misfortune, says Jonathán Torres.